Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared with Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients with Primary Hyperlipidemia or Mixed Dyslipidemia

P. Elliott Miller, Seth S. Martin, Parag H. Joshi, Steven R. Jones, Joseph M. Massaro, Ralph B. D'Agostino, Craig A. Sponseller, Peter P. Toth

Internal Medicine
Cardiology

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Fingerprint

Dive into the research topics of 'Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared with Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients with Primary Hyperlipidemia or Mixed Dyslipidemia'. Together they form a unique fingerprint.

Sort by
Weight
Alphabetically

Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared with Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients with Primary Hyperlipidemia or Mixed Dyslipidemia

Fingerprint

Medicine & Life Sciences